Summary:
CD56
+ lymphomas occur frequently in the nasal or nasopharyngeal region, and account for almost half of nasal or nasopharyngeal lymphomas. 1 They are recognized as a distinct clinicopathologic entity according to the REAL classification, because they frequently show angiocentric and angiodestructive growth.
2 CD56 + lymphomas occurring in other extranodal sites have been reported. [3] [4] [5] Previous reports have shown that both nasal and non-nasal CD56 + lymphomas carry a poor prognosis. 1, [6] [7] [8] These reports suggest that radiotherapy is effective for local disease, but conventional chemotherapy appeared to be ineffective in the Correspondence: Dr Y Nawa, Division of Hematology, Ehime Prefectural Central Hospital, 83, Kasuga-cho, Matsuyama, Ehime 790-0024, Japan Received 20 August 1998; accepted 25 January 1999 majority of cases. Because of the rarity of the disease, there has been no general consensus in the optimum management of NK cell lymphoma. Innovative treatment modalities are needed to improve treatment outcome. Recently, high-dose chemotherapy with autologous bone marrow support has resulted in improved survival in two patients with localized nasal NK/T cell lymphoma. 9 Here, we report our clinical experience of advanced NK cell lymphoma which was successfully treated with high-dose chemotherapy and syngeneic peripheral blood stem cell transplantation (PBSCT).
Case report
A 16-year-old Japanese girl was admitted to our hospital because of a 1-month history of cough, spiking fever and nasal obstruction. On examination, she had cervical and inguinal lymphadenopathy and massive hepatosplenomegaly. Magnetic resonance imaging (MRI) of the head disclosed a mass in the nasopharyngeal region. Computed tomography (CT) scans of the chest demonstrated mediastinal lymphadenopathy and atelectasis of the right upper lobe. Serum lactate dehydrogenase (LDH) was increased (2021 IU/l). Biopsy of a cervical lymph node showed diffuse infiltration of atypical lymphoid cells with an angiocentric distribution. Immunohistochemical studies supported the diagnosis of NK cell lymphoma; infiltrating lymphoid cells were CD2 + , surface CD3 − , and CD56 + . There was no rearrangement of T cell receptor (TCR) genes. EBV-encoded small RNAs (EBERs) were detected in tumor cells by in situ hybridization. EBV serology was as follows: anti-IgG viral capsid antigen (VCA) was 640-fold, anti-IgM VCA Ͻ10-fold, and anti-EBV nuclear antigen (EBNA) Ͻ10-fold. Bone marrow biopsy was normal without lymphoma cell infiltration. The diagnosis of angiocentric lymphoma (NK cell type) associated with EBV, clinical stage III SE , was confirmed.
The clinical course of the patient is shown in Figure 1 . After three cycles of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone), and three cycles of the second-line chemotherapy consisting of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP), the patient achieved a partial response. Since there was a high risk of treatment failure, high-dose chemotherapy facilitated with PBSCT from her identical EBVseronegative twin was planned 5 months after the diagnosis. For syngeneic PBSCT, peripheral blood stem cells (PBSC) were mobilized by 10 g of granulocyte colony-stimulating factor for 5 consecutive days and collected by leukapheresis from her identical twin, as previously described. 
Discussion
Previous studies on the treatment of NK cell lymphoma have shown that the prognosis for patients with both nasal and non-nasal NK cell lymphoma is generally poor. 1, [6] [7] [8] Radiotherapy was effective for local disease, but durable remission is seen in only 50% of stage I patients and the combined use of chemotherapy and radiotherapy has not significantly improved prognosis. Patients with advanced disease almost all die despite intensive chemotherapy with or without additional radiotherapy. Relapse or disease progression usually occur shortly after treatment despite good responses to initial therapy. CD56 expression (neural cell adhesion molecule; NCAM) and frequent expression of a multidrug resistance (P-glycoprotein) phenotype may contribute to the poor prognosis in this disease. 1, 12 The former may facilitate tumor cell migration and dissemination because of the cell adhesion molecule properties of CD56. The latter may explain resistance to a variety of chemotherapeutic regimens. To improve the treatment outcome of NK cell lymphomas, high-dose chemotherapy is considered to be one of the treatment choices which can overcome multidrug resistance. Recently, Liang et al 9 showed that highdose chemotherapy and autologous bone marrow transplantation improved survival in two patients with relapsed nasal NK/T cell lymphoma, and durable complete remission was obtained. Teshima et al 13 chose allogeneic bone marrow transplantation for the treatment of NK cell leukemia and reported an encouraging result. We have demonstrated that high-dose chemotherapy with syngeneic PBSCT was effective in the treatment of refractory NK cell lymphoma. The patient is surviving in continuous complete remission more than 30 months after transplantation. With others, our clinical experience suggests that high-dose chemotherapy and hematopoietic stem cell support may be effective as a salvage treatment for relapsed or refractory NK cell lymphoma. More patients with longer follow-up are required to assess the efficacy of this treatment modality.
